

DEPARTMENTS

52 Reflections

John Jacob Abel: The Fifth Horseman
Rebecca J. Anderson

61 CrossTalk

Conversation with Jean-Pierre Changeux

68 Therapeutic Windows

Visions of drug discovery

97 Beyond the Bench

Out to Lunch
Amy Wecker and Lynn Wecker

99 NetResults

Sites of Interest on the World Wide Web

100 On Deck

Upcoming Meetings

104 Outliers

mi cartoon

EDITOR

Harry B. Smith

ASSOCIATE EDITOR

John W. Nelson

DESIGN & LAYOUT

Vizuál, Inc.

EDITORIAL ADVISORY BOARD

John S. Lazo, Chair, *U Pittsburgh*
Darrell R. Abernethy, *NIH/NIA*
Susan Amara, *U Pittsburgh*
Leslie Z. Benet, *UCSF*
Joan Heller Brown, *UCSD*
Bryan Cox, *Abbott*
Raymond Dingleline, *Emory U*
Sue Duckles, *UC Irvine*
Christopher Flores, *J&J*
Randy Hall, *Emory U*
Ken Harden, *U North Carolina*
John Hickman, *Servier*
Robert S. Kass, *Columbia U*
Serrine S. Lau, *U Arizona*
Benedict Lucchesi, *U Michigan*
Kenneth P. Minneman, *Emory U*
Perry Molinoff, *U Pennsylvania*
Richard R. Neubig, *U Michigan*
Stefan Offermanns, *U Heidelberg*
Carlo Patrono, *U Rome*
Dan Roden, *Vanderbilt*
David Roman, *U Iowa*
Alan Sartorelli, *Yale U*
Darryle D. Schoepp, *Merck*
Boris Tabakoff, *U Colorado*
Palmer Taylor, *UCSD*
Ted Torphy, *Johnson&Johnson*
Roger Tsien, *UCSD*
Michael R. Vasko, *U Indiana*
Mary Vore, *U Kentucky*
Richard M. Weinsilboum, *Mayo*

BOARD OF PUBLICATIONS TRUSTEES

James E. Barrett, Chair
P. Jeffrey Conn
Ross Feldman
Lorraine Gudas
Eric F. Johnson
John S. Lazo
Edward T. Morgan
Richard R. Neubig
Rick G. Schnellmann
Darryle D. Schoepp
Mary Vore

EXECUTIVE OFFICER

Christine K. Carrico

JOURNALS DIRECTOR

Richard Dodenhoff

Molecular Interventions (ISSN 1534-0384) is published by the American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Published bimonthly in February, April, June, August, October, and December. Annual subscription rates: U.S.: \$240 for institutions; and \$78 for individuals. Outside the U.S.: \$261 for institutions and \$99 for individuals. The subscription price to ASPET members (\$30) is included in membership dues. Single issue: \$44. Subscriptions include access to the online version of *MI* at molinterv.org (ISSN 1543-2548). Indexed or abstracted by Biochemistry & Biophysics Citation Index, EMBASE/Excerpta Medica, Index to Scientific Reviews, ISI Alerting Services, ISI Web of Science, PubMed/Medline, and Science Citation Index-Expanded.

Advertising (FASEB AdNet): 301-634-7103; adnet@faseb.org.
Editorial: 301-634-7790; mi@aspet.org. **Subscriptions**: 301-634-7099; staff@dues.faseb.org. **ASPET**: 301-634-7099; info@aspet.org.

Statements and opinions contained in the articles of *Molecular Interventions* are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in *Molecular Interventions* is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Molecular Interventions is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. Photocopying of articles beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law is allowed, provided that the \$20.00 per-copy fee is paid through the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying. Reproduction of any portion of an article for subsequent republication requires permission of the copyright owner. Write to ASPET Copyright Dept., 9650 Rockville Pike, Bethesda, MD 20814-3995.

Postmaster: Send address changes to *Molecular Interventions*, ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995.

molecular interventions


pharmacological perspectives from biology, chemistry and genomics

VIEWPOINTS

70 New Ways of Killing: Novel Targets to Inhibit HIV-1 Replication

More than twenty-five years after its discovery, HIV-1 remains one of the world's most formidable and destructive pathogens. Several classes of anti-HIV-1 agents are currently in widespread clinical use in developed nations; however, viral resistance to these drugs limits their effectiveness in a growing number of patients. It is therefore imperative that novel drugs be developed. Recent advances in the fields of HIV-1 molecular virology and cell biology have revealed possible new targets for drug discovery. The current status of antiretroviral therapy and some of the promising new targets against which novel antiviral agents could be developed are discussed.

Catherine S. Adamson and Eric O. Freed




page 70
Can new agents deliver?

75 Does Improved Lipophilicity Improve Dual Endothelin Receptor Antagonism?


The widespread actions of endothelin-1 (ET-1) and its receptors, ET_A and ET_B, have led to extreme interest in endothelin antagonists for the treatment of various cardiovascular and other disorders. The first commercially available antagonist, bosentan, blocks both receptors and has been successfully marketed for the treatment of pulmonary arterial hypertension. Similarly, selective ET_A receptor antagonists, such as ambrisentan and sitaxentan, have been approved for the same indication in most countries. However, debate remains as to whether selective ET_A blockade or dual ET_{A/B} blockade would provide a therapeutic advantage. Despite the demonstrated clinical utility of endothelin receptor antagonists, there is much room for improvement in the “-sentan” class of drugs. Recently, investigators reported

the development of a new dual endothelin receptor antagonist, macitentan. A specific goal of the drug discovery process, of which macitentan was the end product, was to improve tissue-targeting by selecting lipophilic agents for development. This is a potentially exciting discovery if it can be demonstrated that such compounds partition into local tissue environments to obtain a more preferable pharmacological profile in targeting the largely autocrine-paracrine endothelin system.

David M. Pollock, Erika I. Boesen, Stephen M. Black




page 75
Better tissue partitioning
through chemistry




Location, Location, Location!

MI's review articles in this issue stress the cellular placement (and conformation!) of proteins as a parameter of cell signaling, function, and potential pharmacological regulation. The cover image comes from Jeffrey Martens and his studies of cardiomyocyte potassium channels—including their trafficking through cellular compartments—as targets of antifibrillatory drugs. 🍷



REVIEWS

79 Therapeutic Regulation of K⁺ Channel Surface Expression: Antifibrillatory Agents as “Drug-Traffickers”



page 79
Block the pore,
and more


Atrial fibrillation (AF) is the most common cardiac arrhythmia. The preferred therapy for AF is sustained sinus rhythm control; however, the efficacy of currently used antiarrhythmic drugs is limited by adverse side effects resulting from both a lack of ion channel selectivity and nonspecific ventricular activity. The role of the voltage-gated potassium channels in atrial myocyte repolarization and the subsequent control of action potential duration renders them attractive targets for antiarrhythmic drugs in the treatment of AF. Conventional antiarrhythmic drugs generally target the ion permeability of potassium channels. This review discusses the limitations of this traditional approach and introduces, as a novel paradigm for antiarrhythmic pharmacology, the decrease of ion channel cell surface density through the modulation of ion channel trafficking pathways.

Dyke P. McEwen and Jeffrey R. Martens

87 Biased Agonism Requires Good Location and Receptors to Conform

An activated receptor residing on the cell surface stimulates several intracellular signaling pathways. But what if a cell needs only to activate a subset of those possible pathways? Cells have evolved many ways of tailoring responses, including the use of particular enzyme isoforms and isozymes that have different binding affinities or substrate specificities or are located in differing subcellular compartments. Receptors themselves can regulate what pathways get activated by using the least well-understood mechanism, known as functional selectivity or biased agonism. Depending upon the conformation a receptor adopts and its location on the cell surface, a receptor may specify what intracellular signals are activated. The protease-activated receptor (PAR) family consists of four members that are activated by proteolysis of their extracellular N termini, which unmask an intrinsic cryptic ligand capable of binding the receptor's ligand-binding domain. Differing proteases elicit distinct responses through the activation of the same PAR. This phenomenon can involve localization of the receptors to caveolae-rich lipid rafts and stabilization of distinct active PAR conformations that facilitate selective coupling to different effectors.

Angela Russo, Unice J. K. Soh, and JoAnn Trejo



page 87
Conforming to
expectations?